
Santosh Kesari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8987222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<p>Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives</p> . International Journal of Nanomedicine, 2019, Volume 14, 1937-1952.	6.7	284
2	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1146-1156.	1.2	197
3	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
4	Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell International, 2014, 14, 26.	4.1	152
5	Brain metastases. Current Opinion in Neurology, 2005, 18, 654-661.	3.6	102
6	Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Journal of Translational Medicine, 2014, 12, 13.	4.4	87
7	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget, 2015, 6, 4527-4536.	1.8	85
8	Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget, 2016, 7, 3740-3747.	1.8	61
9	Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. Journal of Translational Medicine, 2015, 13, 269.	4.4	56
10	Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget, 2015, 6, 7293-7304.	1.8	55
11	Protein interaction discovery using parallel analysis of translated ORFs (PLATO). Nature Biotechnology, 2013, 31, 331-334.	17.5	52
12	Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. Journal of Controlled Release, 2014, 183, 146-153.	9.9	45
13	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology, 2016, 18, 849-854.	1.2	45
14	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a <i>post hoc</i> analysis of the EF-14 trial. CNS Oncology, 2017, 6, 185-193.	3.0	43
15	Brainstem Glioma in Adults. Frontiers in Oncology, 2016, 6, 180.	2.8	42
16	Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget, 2015, 6, 1157-1170.	1.8	39
17	Antibody drug conjugates: Progress, pitfalls, and promises. Human Antibodies, 2018, 27, 53-62.	1.5	33
18	Further understanding of the pathology of glioma: implications for the clinic. Expert Review of	2.8	32

² Neurotherapeutics, 2016, 16, 1055-1065.

SANTOSH KESARI

#	Article	IF	CITATIONS
19	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences, 2017, 18, 995.	4.1	32
20	WNT Signaling as a Therapeutic Target for Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 8428.	4.1	32
21	IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. Oncotarget, 2017, 8, 40469-40485.	1.8	30
22	In silico modeling predicts drug sensitivity of patient-derived cancer cells. Journal of Translational Medicine, 2014, 12, 128.	4.4	26
23	A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria. Clinical Cancer Research, 2016, 22, 1445-1458.	7.0	25
24	High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. PLoS ONE, 2013, 8, e56185.	2.5	25
25	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget, 2016, 7, 21556-21569.	1.8	24
26	A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. Journal of Translational Medicine, 2017, 15, 210.	4.4	23
27	Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. Oncotarget, 2017, 8, 22370-22384.	1.8	23
28	Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. Journal of Neuro-Oncology, 2014, 119, 361-368.	2.9	22
29	Anomaly Detection Framework for Wearables Data: A Perspective Review on Data Concepts, Data Analysis Algorithms and Prospects. Sensors, 2022, 22, 756.	3.8	22
30	Xenon in the treatment of panic disorder: an open label study. Journal of Translational Medicine, 2017, 15, 137.	4.4	21
31	Leptomeningeal Metastases. Current Treatment Options in Oncology, 2018, 19, 3.	3.0	20
32	The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: A potential therapeutic opportunity for atherosclerotic thrombosis. Thrombosis Research, 2014, 133, 657-666.	1.7	16
33	Pritumumab, the first therapeutic antibody for glioma patients. Human Antibodies, 2019, 26, 95-101.	1.5	16
34	Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer. Scientific Reports, 2020, 10, 8096.	3.3	15
35	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neuro-Oncology Advances, 2021, 3, vdab142.	0.7	15
36	Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy, 2017, 9, 589-606.	2.0	13

SANTOSH KESARI

#	Article	IF	CITATIONS
37	IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. Scientific Reports, 2020, 10, 8348.	3.3	13
38	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine, 2022, 14, eabb7695.	12.4	13
39	Strategy and Technique of Endonasal Endoscopic Bony Decompression and Selective Tumor Removal in Symptomatic Skull Base Meningiomas of the Cavernous Sinus and Meckel's Cave. World Neurosurgery, 2019, 131, e12-e22.	1.3	12
40	Hyaluronan expression in primary and secondary brain tumors. Annals of Translational Medicine, 2015, 3, 80.	1.7	11
41	Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. American Journal of Roentgenology, 2018, 211, 1342-1347.	2.2	10
42	Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint. Nucleic Acids Research, 2021, 49, 1235-1246.	14.5	10
43	Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. American Journal of Neuroradiology, 2017, 38, 882-889.	2.4	9
44	Isolated Loss of Hormonal Receptors in Leptomeningeal Metastasis From Estrogen Receptor– and Progesterone Receptor–Positive Lobular Breast Cancer. Journal of Clinical Oncology, 2010, 28, e200-e202.	1.6	8
45	Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. Clinical Investigation, 2011, 1, 1391-1402.	0.0	7
46	Cellular target engagement: a new paradigm in drug discovery. Future Medicinal Chemistry, 2018, 10, 1641-1644.	2.3	7
47	Wnt pathway: a hallmark of drug discovery challenge. Future Medicinal Chemistry, 2018, 10, 1399-1403.	2.3	4
48	Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. BioTechniques, 2020, 68, 180-184.	1.8	4
49	Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. Neuro-Oncology Advances, 2021, 3, vdab006.	0.7	4
50	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncology Advances, 2022, 4, .	0.7	4
51	Overcoming tumor immune evasion with an unique arbovirus. Journal of Translational Medicine, 2015, 13, 3.	4.4	3
52	Breaking down the blood–brain barrier. Neuro-Oncology, 2021, 23, 6-6.	1.2	1
53	Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. Leukemia and Lymphoma, 2021, 62, 2044-2046.	1.3	1
54	A community affair in the tumor microenvironment. Oncotarget, 2017, 8, 106173-106174.	1.8	1

#	Article	IF	CITATIONS
55	ATNT-19TUMOR TREATING FIELDS WITH CHEMOTHERAPY COMPARED TO CHEMOTHERAPY ALONE IN GLIOBLASTOMA PATIENTS AT FIRST RECURRENCE: A POST-HOC ANALYSIS OF THE EF-14 TRIAL. Neuro-Oncology, 2015, 17, v14.4-v14.	1.2	0
56	DDEL-17CSF PHARMACOKINETICS AND PHARMACODYNAMICS IN BRAIN CANCER PATIENTS ON HIGH-DOSE ERLOTINIB. Neuro-Oncology, 2015, 17, v77.1-v77.	1.2	0
57	ATPS-64PRECLINICAL STUDIES USING NATIVIS VOYAGER RFE SYSTEM, A NOVEL NON-INVASIVE, LOW ENERGY, NON-THERMAL, NON-IONIZING RADIOFREQUENCY ENERGY (RFE) DEVICE IN GLIOBLASTOMA MOUSE MODELS. Neuro-Oncology, 2015, 17, v32.2-v32.	1.2	0